Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

Monte Rosa Therapeutics (Nasdaq: GLUE) priced an underwritten public offering of 11,125,000 common shares at $24.00 per share and pre-funded warrants to purchase 1,375,000 shares at $23.9999 each.

Rhea-AI Summary

Monte Rosa Therapeutics (Nasdaq: GLUE) priced an underwritten public offering of 11,125,000 common shares at $24.00 per share and pre-funded warrants to purchase 1,375,000 shares at $23.9999 each. Gross proceeds are expected to be approximately $300 million, before underwriting discounts, commissions and expenses. The company granted underwriters a 30-day option to buy up to an additional 1,875,000 shares. All offered securities are being sold by Monte Rosa and the offering is expected to close on or about January 12, 2026, subject to customary closing conditions.

Jefferies, TD Cowen and Piper Sandler are joint book-running managers; Wedbush PacGrow and LifeSci Capital are passive bookrunners. The offering is made under an effective shelf registration statement declared effective March 31, 2025.

Positive

• Expected gross proceeds of $300 million
• Includes pre-funded warrants allowing flexible issuance
• Underwriters include major firms Jefferies, TD Cowen, Piper Sandler

Negative

• Issuance may cause share dilution for existing holders
• Underwriters hold a 30-day option for 1,875,000 additional shares

Argus Jan 9 session

-4.07% close to close Open Argus

Details

News Market Reaction – GLUE

On Jan 9, the first trading day after this news, GLUE closed 4.07% below the previous close.

Data tracked by StockTitan Argus for the Jan 9 session.

Key Figures

Common shares offered: 11,125,000 shares Offering price: $24.00 per share Pre-funded warrants: 1,375,000 warrants +5 more

Common shares offered

11,125,000 shares

Underwritten public offering size

Offering price

$24.00 per share

Public offering price for common stock

Pre-funded warrants

1,375,000 warrants

In lieu of common stock for certain investors

Pre-funded warrant price

$23.9999 per warrant

Public offering price for pre-funded warrants

Exercise price

$0.0001 per share

Exercise price of each pre-funded warrant

Underwriters’ option

1,875,000 shares

30-day option to buy additional common shares

Expected gross proceeds

$300 million

Before discounts, commissions and expenses; excludes underwriters’ option

Expected closing date

January 12, 2026

Expected closing of the underwritten public offering

Historical Context

5 past events · Latest: Jan 07

5 events

1. Jan 07

   Equity offering plan

   24h Move

   +45.4%

   Proposed underwritten offering of common stock and pre-funded warrants.

2. Jan 07

   Clinical data update

   24h Move

   +45.4%

   Positive interim Phase 1 data for MRT-8102 with strong biomarker effects.

3. Jan 06

   Data presentation plan

   24h Move

   +11.2%

   Announcement of upcoming interim MRT-8102 Phase 1 results presentation.

4. Dec 16

   Clinical data update

   24h Move

   +13.4%

   Interim MRT-2359 plus enzalutamide data showing high response and control rates.

5. Dec 15

   Data presentation plan

   24h Move

   +0.9%

   Notice of upcoming presentation of updated MRT-2359 Phase 1/2 results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten public offering, pre-funded warrants, exercise price, prospectus supplement, +4 more

8 terms

underwritten public offering financial

"announced the pricing of an underwritten public offering of 11,125,000 shares"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

pre-funded warrants financial

"in lieu of common stock to certain investors, pre-funded warrants to purchase"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

exercise price financial

"less the $0.0001 per share exercise price for each pre-funded warrant"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

prospectus supplement regulatory

"A preliminary prospectus supplement relating to and describing the terms"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

registration statement regulatory

"that form a part of the registration statement"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

joint book-running managers financial

"Jefferies, TD Cowen and Piper Sandler are acting as joint book-running managers"

Joint book-running managers are the lead banks or financial firms responsible for organizing and overseeing the sale of a large financial offering, such as a company’s stock or bonds. They coordinate efforts to set the price, attract investors, and ensure the offering is successful. Their role is important to investors because they help ensure the offering is well-managed, properly priced, and accessible to a wide range of buyers.

passive bookrunners financial

"Wedbush PacGrow and LifeSci Capital are acting as passive bookrunners"

Passive bookrunners are financial firms listed on an offering’s team who help record investor interest but do not actively market the deal, push the price, or take on firm underwriting risk. For investors, that means less hands-on selling and price support from those firms—so demand, final price, and short-term share stability depend more on the lead underwriters and natural investor appetite, much like a group of helpers who note orders but leave the negotiations and follow-up to the main negotiators.

molecular glue degrader medical

"developing novel molecular glue degrader (MGD)-based medicines"

A molecular glue degrader is a small drug-like molecule that acts like a tiny adhesive, sticking a specific disease-related protein to the cell’s natural disposal machinery so the protein is destroyed rather than merely blocked. Investors watch these compounds because they can turn previously untreatable targets into removable liabilities, potentially creating breakthrough therapies, shifting development risk, and offering strong commercial upside if clinical results and regulatory approval follow.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwritten public offering of 11,125,000 shares of its common stock at a public offering price of $24.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,375,000 shares of common stock at a public offering price of $23.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. Monte Rosa also granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Monte Rosa from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $300 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares and pre-funded warrants in the offering are to be sold by Monte Rosa. The offering is expected to close on or about January 12, 2026, subject to satisfaction of customary closing conditions.

Jefferies, TD Cowen and Piper Sandler are acting as joint book-running managers for the offering. Wedbush PacGrow and LifeSci Capital are acting as passive bookrunners for the offering.

The shares and pre-funded warrants are being offered by Monte Rosa pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC) on March 20, 2025 and declared effective by the SEC on March 31, 2025 (File No. 333-285942). The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov.

The final prospectus supplement relating to and describing the final terms of the offering will be filed with the SEC and may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com, TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, email at TDManualrequest@broadridge.com, Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com, Wedbush Securities Inc., Attn: ECM Department, 600 Montgomery Street, 29th Floor, San Francisco, CA 94111 or via email at ecm@wedbush.com or LifeSci Capital LLC at 1700 Broadway, 40th Floor, New York, New York 10019, or by email at compliance@lifescicapital.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology and neurology.

Forward-Looking Statements 

This press release includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Monte Rosa’s expectations regarding the timing and closing of the public offering, including the satisfaction of customary closing conditions related to the offering. Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward- looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. These and the risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Monte Rosa’s most recent Annual Report on Form 10-K, as well as the most recent Quarterly Reports on Form 10-Q and any subsequent filings with the SEC. In addition, any forward-looking statements represent Monte Rosa’s views only as of as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Monte Rosa explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investors  
Andrew Funderburk
ir@monterosatx.com 

Media  
Cory Tromblee, Scient PR
media@monterosatx.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Monte Rosa (GLUE) offer in the January 2026 public offering?

Monte Rosa offered 11,125,000 common shares plus pre-funded warrants for 1,375,000 shares.

What price did Monte Rosa (GLUE) set for the January 2026 offering?

The public offering price was $24.00 per common share and $23.9999 per pre-funded warrant.

How much gross proceeds will Monte Rosa (GLUE) receive from the offering?

Gross proceeds are expected to be approximately $300 million, before underwriting discounts and expenses.

When is the Monte Rosa (GLUE) offering expected to close?

The offering is expected to close on or about January 12, 2026, subject to customary closing conditions.

Do underwriters have an option to buy more Monte Rosa (GLUE) shares?

Yes. Underwriters have a 30-day option to purchase up to 1,875,000 additional shares at the offering price.

Who are the lead managers for Monte Rosa's (GLUE) public offering?

Jefferies, TD Cowen and Piper Sandler are joint book-running managers; Wedbush PacGrow and LifeSci Capital are passive bookrunners.